Verrica Pharmaceuticals (VRCA) Profit After Tax (2017 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Profit After Tax of -$9.7 million for Q1 2026, up 0.62% year-over-year from -$9.6 million in Q1 2025, and down 19.92% quarter-over-quarter from -$8.1 million in Q4 2025.
Verrica Pharmaceuticals (VRCA) Profit After Tax (2017 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Profit After Tax history runs 10 years deep, the most recent figure standing at -$9.7 million for Q1 2026.
- In Q1 2026, Profit After Tax rose 0.62% year-over-year to -$9.7 million; the TTM figure through Mar 2026 stood at -$17.8 million (up 72.99% YoY), while the FY2025 annual figure was -$17.9 million, up 76.64% from the prior year.
- Profit After Tax for Q1 2026 stood at -$9.7 million, down from -$8.1 million in the prior quarter.
- The five-year high for Profit After Tax was $204000.0 in Q2 2025, with the low at -$24.8 million in Q3 2023.
- The 5-year median for Profit After Tax is -$9.7 million (2025), against an average of -$11.5 million.
- The sharpest annual moves came in 2023 and 2025: Profit After Tax tumbled 29981.93% in 2023, then surged 101.19% in 2025.
- Verrica Pharmaceuticals' Profit After Tax stood at -$5.9 million in 2022, then slumped by 316.97% to -$24.6 million in 2023, then soared by 34.18% to -$16.2 million in 2024, then jumped by 50.17% to -$8.1 million in 2025, then dropped by 19.92% to -$9.7 million in 2026.
- Business Quant data shows VRCA's Profit After Tax at -$9.7 million in Q1 2026, -$8.1 million in Q4 2025, and -$274000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Verrica Pharmaceuticals | 102.80 Mn | 91.60 Mn | - | -13.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.15 Mn |
| Mar 31, 2026 | -9.68 Mn |
| Dec 31, 2025 | -8.07 Mn |
| Sep 30, 2025 | -274,000.00 |
| Jun 30, 2025 | 204,000.00 |
| Mar 31, 2025 | -9.74 Mn |
| Dec 31, 2024 | -16.20 Mn |
| Sep 30, 2024 | -22.86 Mn |
| Jun 30, 2024 | -17.19 Mn |
| Mar 31, 2024 | -20.33 Mn |
| Dec 31, 2023 | -24.61 Mn |
| Sep 30, 2023 | -24.80 Mn |
| Jun 30, 2023 | -10.99 Mn |
| Mar 31, 2023 | -6.59 Mn |
| Dec 31, 2022 | -5.90 Mn |
| Sep 30, 2022 | 83,000.00 |
| Jun 30, 2022 | -10.17 Mn |
| Mar 31, 2022 | -8.47 Mn |
| Dec 31, 2021 | -9.57 Mn |
| Sep 30, 2021 | -12.83 Mn |